Results 1 to 10 of about 8,238 (80)

Vedolizumab [PDF]

Reactions Weekly, 2020
  +6 more sources

Efficacy and health-related quality of life associated with second-line vedolizumab after first-line treatment with one anti-TNF in patients with ulcerative colitis: a meta-analysis of the GEMINI-1 and VISIBLE-1 trials. [PDF]

Ther Adv Gastroenterol
Atreya R, Kirchgesner J, Cheah Z, Biedermann P, Bakker L, Meyer M, Raine T.   +6 more
europepmc   +1 more source

Persistence of advanced therapies in patients with ulcerative colitis: real-world data from the nationwide CREdIT registry. [PDF]

Ther Adv Gastroenterol
Hradsky O, Duricova D, Lukas M, Nedbalová L, Pipek B, Drastich P, Falt P, Vanasek T, Svikova J, Siroky M, Bouchner L, Svoboda P, Bronsky J, Bortlik M.   +13 more
europepmc   +1 more source

Vedolizumab and the gut-CNS axis in multiple sclerosis: considering T cell licensing pathways. [PDF]

Ther Adv Neurol Disord
Shirani A, Stuve O.
europepmc   +1 more source

Therapeutic Drug Monitoring of Vedolizumab Levels During Maintenance in Inflammatory Bowel Disease (MOVE-IBD). [PDF]

JGH Open
Logan H, Rimmer K, Doecke J, Patrick D.
europepmc   +1 more source

An Unusual Cluster of Urinary Tract Infections, Including Salmonella spp., in an Iranian Ulcerative Colitis Cohort Treated With Vedolizumab: A Case Series and Comparative Analysis. [PDF]

JGH Open
VatanParast Y.
europepmc   +1 more source

The Development of Sarcoidosis in an Ulcerative Colitis Patient Treated with Vedolizumab: A Case Report and Review of the Literature. [PDF]

Clin Pract
Triantafillidis JK, Malgarinos K, Kaklamanis L, Kritsotakis E, Polydorou V, Pantos K, Sfakianoudis K, Pantou A, Bramis K, Konstantoulakis MM, Papalois AE.   +10 more
europepmc   +1 more source

Final results from the vedolizumab extended access program multinational study demonstrate long-term treatment persistence and safety. [PDF]

Ther Adv Gastroenterol
Danese S, Lukáš M, Volfová M, Rydzewska G, Adsul S, Lindner D, Jones S, Vermeire S.   +7 more
europepmc   +1 more source

Vedolizumab-induced Bullous Pemphigoid: A Case Report with Serological Evidence and Mechanistic Insights. [PDF]

Acta Derm Venereol
Feng X, Li J, Li X, Zhang Y, Li W.
europepmc   +1 more source

Association of tissue lymphocyte immunophenotype and clinical outcomes: A prospective study in patients with ulcerative colitis treated with vedolizumab. [PDF]

PLoS One
Ando K, Kashima S, Sakatani A, Konishi H, Maemoto A, Ito T, Taruishi M, Hamagami K, Ishiguro K, Fujiya M.   +9 more
europepmc   +1 more source